Inside the Market of Emerging Biotechs

For nearly a decade, biotech companies and their venture backers enjoyed a historic boom. Although momentum has come to a halt, many of the largest venture investors remain flush with cash, while progress in gene editing, messenger RNA and cell therapies promise new kinds of medicines in the future.

INCLUDED IN THIS TRENDLINE

• In a year with few biotech IPOs, ‘crossover’ financings are hard to find
• Early-stage biotech funding in 2023 lagging behind previous years’ pace
• F-Prime’s Ketan Patel on ‘reverse ageism’ in biotech and investing in a downturn

Request Free!